These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38008300)

  • 1. Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem cell transplantation.
    Gakis G; Angelopoulos I; Panagoulias I; Mouzaki A
    Autoimmun Rev; 2024 Feb; 23(2):103480. PubMed ID: 38008300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.
    Brittain G; Petrie J; Duffy KEM; Glover R; Hullock K; Papaioannou D; Roldan E; Beecher C; Bursnall M; Ciccarelli O; Coles AJ; Cooper C; Giovannoni G; Gabriel I; Kazmi M; Kyriakou C; Nicholas R; Paling D; Peniket A; Scolding N; Silber E; de Silva T; Venneri A; Walters SJ; Young C; Muraro PA; Sharrack B; Snowden JA;
    BMJ Open; 2024 Feb; 14(2):e083582. PubMed ID: 38316583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
    Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
    Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.
    Boffa G; Signori A; Massacesi L; Mariottini A; Sbragia E; Cottone S; Amato MP; Gasperini C; Moiola L; Meletti S; Repice AM; Brescia Morra V; Salemi G; Patti F; Filippi M; De Luca G; Lus G; Zaffaroni M; Sola P; Conte A; Nistri R; Aguglia U; Granella F; Galgani S; Caniatti LM; Lugaresi A; Romano S; Iaffaldano P; Cocco E; Saccardi R; Angelucci E; Trojano M; Mancardi GL; Sormani MP; Inglese M;
    Neurology; 2023 Mar; 100(11):e1109-e1122. PubMed ID: 36543569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation.
    Ismail A; Sharrack B; Saccardi R; Moore JJ; Snowden JA
    Curr Opin Support Palliat Care; 2019 Dec; 13(4):394-401. PubMed ID: 31599815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.
    Vaivade A; Wiberg A; Khoonsari PE; Carlsson H; Herman S; Al-Grety A; Freyhult E; Olsson-Strömberg U; Burman J; Kultima K
    Lipids Health Dis; 2023 Jul; 22(1):97. PubMed ID: 37420217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
    Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
    J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis.
    Burt RK; Han X; Quigley K; Helenowski IB; Balabanov R
    J Neurol; 2022 May; 269(5):2513-2526. PubMed ID: 34633525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.
    Boyko A; Therapontos C; Horakova D; Szilasiová J; Kalniņa J; Kolontareva J; Gross-Paju K; Selmaj K; Sereike I; Milo R; Gabelić T; Rot U
    Mult Scler Relat Disord; 2021 May; 50():102778. PubMed ID: 33592384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient.
    Obradović D; Tukić L; Radovinović-Tasić S; Petrović B; Elez M; Ostojić G; Balint B
    Vojnosanit Pregl; 2016 May; 73(5):504-8. PubMed ID: 27430119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis.
    Mariottini A; Nozzoli C; Carli I; Landi F; Gigli V; Repice AM; Ipponi A; Cecchi M; Boncompagni R; Saccardi R; Massacesi L
    Neurol Sci; 2024 Jul; 45(7):3379-3387. PubMed ID: 38277051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous hematopoietic stem cell transplantation (AHSCT) for aggressive multiple sclerosis - whom, when and how.
    Szczechowski L; Śmiłowski M; Helbig G; Krawczyk-Kuliś M; Kyrcz-Krzemień S
    Int J Neurosci; 2016 Oct; 126(10):867-71. PubMed ID: 26577419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies.
    Amoriello R; Greiff V; Aldinucci A; Bonechi E; Carnasciali A; Peruzzi B; Repice AM; Mariottini A; Saccardi R; Mazzanti B; Massacesi L; Ballerini C
    Front Immunol; 2020; 11():559. PubMed ID: 32328061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ongoing randomized clinical trials on HSCT in multiple sclerosis.
    Inglese M; Cohen JA; Sharrack B; Boffa G
    Handb Clin Neurol; 2024; 202():307-315. PubMed ID: 39111916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: a PRISMA-compliant meta-analysis.
    Zhang P; Liu B
    Bone Marrow Transplant; 2020 Oct; 55(10):1928-1934. PubMed ID: 32020080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future.
    Gholamzad M; Ebtekar M; Ardestani MS; Azimi M; Mahmodi Z; Mousavi MJ; Aslani S
    Inflamm Res; 2019 Jan; 68(1):25-38. PubMed ID: 30178100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multiple sclerosis: interventions to halt disease : Which patients can be considered for autologous stem cell transplantation].
    Willison AG; Meuth SG
    Nervenarzt; 2022 Oct; 93(10):987-999. PubMed ID: 35951049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-reported changes in the expanded disability status scale score in patients with multiple sclerosis after autologous stem cell transplants: real-world data from a single center.
    Ruiz-Argüelles GJ; Olivares-Gazca JC; Olivares-Gazca M; Leon-Peña AA; Murrieta-Alvarez I; Cantero-Fortiz Y; Gomez-Cruz GB; Ruiz-Argüelles A; Priesca-Marin M; Ruiz-Delgado GJ
    Clin Exp Immunol; 2019 Dec; 198(3):351-358. PubMed ID: 31394007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economics of hematopoietic stem cell transplant in immune-mediated neurologic autoimmune diseases.
    Hughes SL; Prettyjohns MJ; Snowden JA; Sharrack B
    Handb Clin Neurol; 2024; 202():279-294. PubMed ID: 39111914
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.